3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: A self-organizing molecular field analysis approach

Medicinal Chemistry

Volumn 6, Issue 1, 2010, Pages 30-36

  Thareja, Suresh ^a   Aggarwal, Saurabh ^a   Bhardwaj, Tilak Raj ^a   Kumar, Manoj ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3D QSAR; Aldose reductase; Diabetes; Diabetic complications; SOMFA; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 ARYLIDINE 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; ELECTRICITY; ENZYME INHIBITION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SELF ORGANIZING MOLECULAR FIELD ANALYSIS; VALIDATION PROCESS;

ALDEHYDE REDUCTASE; DIABETES COMPLICATIONS; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 77950883461     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340610791208718     Document Type: Article

References (38)

1. Skyler, J. S. Diabetes mellitus: Pathogenesis and treatment strategies. J. Med. Chem., 2004, 47, 4113-4117. (Pubitemid 39045414)
2. Brown, M. A tale of two necessities: breakaway technology versus diabetes. Drug Disc. Today, 2003, 8, 561-562. (Pubitemid 36875714)
3. Vats, R.K.; Kumar, V.; Kothari, A.; Mital, A.; Ramachandaran, V. Emerging targets for diabetes. Curr. Sci., 2005, 88, 241-249.
4. Suzen, S.; Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem., 2003, 10, 1329-1352. (Pubitemid 36896564)
5. Kinoshita, J. H.; Kador, P.; Catiles, M. Aldose reductase in diabetic cataracts. JAMA, 1981, 246, 257-261.
6. Carper, D.; Nishimura, C.; Shinohara, T.; Dietzchold, B.; Wistow, G.; Craft, C.; Kador, P.; Kinoshita, J. H. Aldose reductase and [var-rho]-crystallin belong to the same protein superfamily as aldehyde reductase. FEBS Lett., 1987, 220, 209-213.
7. Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem., 2002, 28, 841-849.
8. Severi, F.; Benvenuti, S.; Costantino, L.; Vampa, G.; Melegari, M.; Antolini, L. Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. Eur. J. Med. Chem., 1998, 33, 859-866.
9. Maccari, R.; Ottanà, R.; Ciurleo, R.; Rakowitz, D.; Matuszczak, B.; Laggner, C.; Langer, T. Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. Bioorg. Med. Chem., 2008, 16, 5840-5852. (Pubitemid 351758852)
10. Bozdag-Dündar, O.; Verspohl, E. J.; Das-Evcimen, N.; Kaup, R. M.; Bauer, K.; SarIkaya, M.; Evranos, B.; Ertan, R. Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg. Med. Chem., 2008, 16, 6747-6751. (Pubitemid 351498508)
11. Sarges, R.; Bordner, J.; Dominy, B. W.; Peterson, M. J.; Whipple, E. B. Synthesis, absolute configuration and conformation of the aldose reductase inhibitor sorbinil. J. Med. Chem., 2002, 28, 1716-1720.
12. Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2- benzothiazolyl]methyl]-1-phthalazineaceticacid (zopolrestat) and congeners. J. Med. Chem., 2002, 34, 108-122.
13. El-Kabbani, O.; Carbone, V.; Darmanin, C.; Oka, M.; Mitschler, A.; Podjarny, A.; Schulze-Briese, C.; Chung, R. P. T. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. J. Med. Chem., 2005, 48, 5536-5542. (Pubitemid 41209251)
14. Hotta, N.; Kakuta, H.; Ando, F.; Sakamoto, N. Current progress in clinical trials of aldose reductase inhibitors in Japan. Exp. Eye Res., 1990, 50, 625-628. (Pubitemid 20191290)
15. Bhat, B. A.; Ponnala, S.; Sahu, D. P.; Tiwari, P.; Tripathi, B. K.; Srivastava, A. K. Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives. Bioorg. Med. Chem., 2004, 12, 5857-5864. (Pubitemid 39388184)
16. da Costa Leite, L. F. C.; Veras Mourão, R. H.; de Lima, M. d. C. A.; Galdino, S. L.; Hernandes, M. Z. Synthesis, biological evaluation and molecular modeling studies of arylidenethiazolidinediones with potential hypoglycemic and hypolipidemic activities. Eur. J. Med. Chem., 2007, 42, 1263-1271.
17. Bozdag-Dundar, O.; Evcimen, N. D.; Ceylan-Unlusoy, M.; Ertan, R.; Sarikaya, M. Some new thiazolyl thiazolidinedione derivatives as aldose reductase inhibitor. Med. Chem. Res., 2007, 16, 39-47.
18. Robinson, D. D.; Winn, P. J.; Lyne, P. D.; Richards, W. G. Self-organizing molecular field analysis: a tool for structure-activity studies. J. Med. Chem., 1999, 42, 573-583. (Pubitemid 29110773)
19. Cramer, R. D., III; Patteerson, D. E.; Bunce, J.D. Comparative Molecular Field Analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
20. Li, S.; Zheng, Y. Self-organizing molecular field analysis on a new series of COX-2 selective inhibitors: 1, 5-Diarylimidazoles. Int. J. Mol. Sci., 2006, 7, 220-229. (Pubitemid 44180787)
21. 1a-Adrenoceptor dihydropyridine antagonists. Bioorg. Med. Chem., 2003, 11, 3945-3951.
22. Thareja, S.; Aggarwal, S.; Bhardwaj, T. R.; Kumar, M. Self organizing molecular field analysis on a series of human 5α reductase inhibitors: Unsaturated 3-carboxysteroid. Eur. J. Med. Chem., 2009, 44, 4920-4925.
23. Bruno, G.; Costantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolò, F.; Ottanà, R.; Vigorita, M. G. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem., 2002, 10, 1077-1084. (Pubitemid 34139922)
24. Murthy, V. S.; Kulkarni, V. M. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem., 2002, 10, 2267-2282. (Pubitemid 34450917)
25. Aggarwal, S.; Thareja, S.; Bhardwaj, T. R.; Kumar, M. 3D-QSAR studies on unsaturated 4-Azasteroids as Human 5α-Reductase Inhibitors: A Self Organizing Molecular Field Analysis Approach. Eur. J. Med. Chem., 2009 (Article in press) Doi: 10.1016/j.ejmech.2009.10.030.
26. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models am1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 1985, 107, 3902-3909.
27. Stewart, J. MOPAC: A semiempirical molecular orbital program. J. Comput. Aid. Mol. Des., 1990, 4, 1-105
28. 1a receptor ligands by the method of comparative molecular field analysis. J. Comput. Chem., 1993, 14, 237-245.
29. Baurin, N.; Vangrevelinghe, E.; Allory, L.M. 3D-QSAR CoMFA study on imidazolinergic i2 ligands: a significant model through a combined exploration of structural diversity and methodology. J. Med. Chem., 2000, 43, 1109-1122.
30. Xu, M.; Zhang, A.; Han, S.; Wang, L. Studies of 3D-quantitative structure-activity relationships on a set of nitroaromatic compounds: CoMFA advanced CoMFA and CoMSIA. Chemosphere, 2002, 48, 707-715. (Pubitemid 34815113)
31. Pedretti, A.; Villa, L.; Vistoli, G. VEGA: A versatile program to convert, handle and visualize molecular structures on windows-based PCs. J. Mol. Graph. Model., 2002, 21, 47-49.
32. VEGA ZZ Release 2.0.5.52, can be downloaded From: http://www.ddl.unimi. it/vega/index2.htm
33. SOMFA2 v2.0.0 can be downloaded from: http://bellatrix.pcl.ox.ac.uk(2006) .
34. 1-adrenoceptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 3216-3219.
35. Kulkarni, S. S.; Gediya, L. K.; Kulkarni, V. M. Three-Dimensional Quantitative Structure Activity Relationships (3D-QSAR) of antihyperglycemic agents. Bioorg. Med. Chem. Lett., 1999, 7, 1475-1485.
36. 2! J. Mol. Graph. Model. 2002, 20, 269-276.
37. Puntambekar, D. S.; Giridhar, R.; Yadav, M. R. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and COMSIA models. Eur. J. Med. Chem., 2008, 43, 142-154.
38. Puntambekar, D.; Giridhar, R.; Yadav, M. R. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. Bioorg. Med. Chem. Lett., 2006, 16, 1821-1827.